191 results about "Gastrointestinal system" patented technology

The present invention relates to compositions and methods for the administration of lipid-based vehicles to treat various disorders, including bladder inflammation, infection, dysfunction, and cancer. In various aspects, the compositions and methods of the invention are useful for prolonged delivery of drugs, e.g., antibiotics, pain treatments, and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system, and other organs or body systems. In particular, the present invention relates to liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin, and toxins, such as botulinum toxin, for the treatment of bladder conditions, including pain, inflammation, incontinence, and voiding dysfunction. Further related are methods of using these vehicles alone or in conjunction with antibodies, e.g., uroplakin antibodies, to improve duration of liposome attachment, and provide a long-term intravesical drug delivery platform. The present invention specifically relates to antibody-coated liposomes that are useful for targeting specific receptors for drug, peptide, polypeptide, or nucleic acid delivery. In one particular aspect, the present invention relates to liposomes coated with antibodies against nerve growth factor (NGF) receptor and containing NGF antisense nucleic acids, which are used as a treatment for neurogenic bladder dysfunction.

Apparatus and methods for positioning and securing anchors are disclosed herein. The anchors are adapted to be delivered and implanted into or upon tissue, particularly tissue within the gastrointestinal system of a patient. The anchor is adapted to slide uni-directionally over suture such that a tissue plication may be cinched between anchors. A locking mechanism either within the anchor itself of positioned proximally of the anchor may allow for the uni-directional translation while enabling the anchor to be locked onto the suture if the anchor is pulled, pushed, or otherwise urged in the opposite direction along the suture. This unidirectional anchor locking mechanism facilitates the cinching of the tissue plication between the anchors and it may be utilized in one or several anchors in cinching a tissue fold.

Apparatus and methods for positioning and securing anchors are disclosed herein. The anchors are adapted to be delivered and implanted into or upon tissue, particularly tissue within the gastrointestinal system of a patient. The anchor is adapted to slide uni-directionally over suture such that a tissue plication may be cinched between anchors. A locking mechanism either within the anchor itself of positioned proximally of the anchor may allow for the uni-directional translation while enabling the anchor to be locked onto the suture if the anchor is pulled, pushed, or otherwise urged in the opposite direction along the suture. This uni-directional anchor locking mechanism facilitates the cinching of the tissue plication between the anchors and it may be utilized in one or several anchors in cinching a tissue fold.

A device useful for oral drug delivery device consisting of: (a) a capsule, tablet or pill designed to disperse in the gastrointestinal system; (b) an RFID tag positioned in the capsule, tablet or pill, the RFID tag comprising an antenna; (c) an object selected from the group consisting of a magnet, a ferromagnetic object, a ferrite object and an electromagnetic shielding object positioned within, over or adjacent the antenna of the RFID tag to alter the antenna characteristics of the RFID tag so that if the RFID tag is interrogated before the capsule, tablet or pill disperses in the gastrointestinal system, the response of the RFID tag is sufficiently altered or attenuated to determine that the capsule, tablet or pill has not dispersed in the gastrointestinal system and so that if the RFID tag is interrogated after the capsule, tablet or pill has dispersed in the gastrointestinal system, the object separates from the RFID tag so that the response of the RFID tag is sufficiently detectable to determine that the capsule, tablet or pill has dispersed in the gastrointestinal system. Alternatively, a switch can be used to signal ingestion of the device, and change the response of the device. In another embodiment, the instant invention is a device useful for oral drug delivery, consisting of: (a) a capsule, tablet or pill designed to disperse in the gastrointestinal system; (b) a first non-anti-collision RFID tag positioned in the capsule; (c) a second non-anti-collision RFID tag positioned in the capsule, so that if the RFID tags are interrogated by an RFID reader before the capsule, tablet or pill disperses in the gastrointestinal system, the response of the RFID tags collide and so that after the dispersible material of the capsule has dispersed in the gastrointestinal system thereby allowing the first and second non-anti-collision tags to separate from each other, then the response of the RFID tags is sufficiently different from each other to determine that the capsule has dispersed in the gastrointestinal system

Apparatus and methods for positioning and securing anchors are disclosed herein. The anchors are adapted to be delivered and implanted into or upon tissue, particularly tissue within the gastrointestinal system of a patient. The anchor is adapted to slide uni-directionally over suture such that a tissue plication may be cinched between anchors. A locking mechanism either within the anchor itself of positioned proximally of the anchor may allow for the uni-directional translation while enabling the anchor to be locked onto the suture if the anchor is pulled, pushed, or otherwise urged in the opposite direction along the suture. This uni-directional anchor locking mechanism facilitates the cinching of the tissue plication between the anchors and it may be utilized in one or several anchors in cinching a tissue fold.

Disclosed is an expandable transluminal sheath, for introduction into the body while in a first, low cross-sectional area configuration, and subsequent expansion of at least a part of the distal end of the sheath to a second, enlarged cross-sectional configuration. The sheath is configured for use in the gastrointestinal system and has utility in the performance of endoscopic retrograde cholangiopancreatography (ERCP). The distal end of the sheath is maintained in the first, low cross-sectional configuration and expanded using a radial dilatation device. In an exemplary application, the sheath is utilized to provide access for a diagnostic or therapeutic procedure such as gallstone or pancreatic stone removal.

A gastrointestinal implant device is positioned in a patient's small intestine or rectum and produces an outward force that itself produces a distension signal which is a therapeutically useful neural or humoral signal that evokes satiogenic or weight loss effects by itself. The device may advantageously be placed in the duodenum adjacent the pylorus or in the jejunum, ileum or rectum. The distension signals may amplify chemosensory or mechanosensory signals such as enteroendocrine secretions within the patient. The device may be a mesh and include a low material density that allows for unrestricted chyme absorption within the small intestine and unrestricted chyme flow through the gastrointestinal system. A method includes inserting the device into the patient then either retrieving the device after treatment is complete or allowing a device formed of a biodegradable material to degrade in time after treatment is complete.

The invention concerns excipients or combinations thereof suitable for preparing an oral formulation containing a pharmaceutical agent. More particularly, the invention is directed to stable, efficacious and bioavailable oral pharmaceutical formulations comprising paclitaxel, derivatives of paclitaxel and pharmaceutically acceptable salts thereof. The formulations of the invention increase bioavailability of paclitaxel when dissolved in the gastrointestinal system. The formulations of the invention are useful for administering paclitaxel, its derivatives, or pharmaceutically acceptable salts of such derivatives to patients in need thereof. The formulations of the invention are particularly suitable for oral administration to mammals including humans.

Disclosed is a swallowable self-expanding gastric space occupying device and related methods of making and using the device to control obesity. The device has a membrane through which gastric liquid can pass, wherein the membrane provides an enclosure volume separated from the gastric environment by the membrane. A plurality of self-expanding components is contained in the enclosure volume, so that the components expand in volume upon contact with the gastric fluid, thereby expanding the device from an unexpanded volume to an expanded volume. Composite membranes provide the ability to precisely control how and when the membrane degrades in the stomach, to release the self-expanding components from the enclosure and to ensure that the released pieces are sufficiently small to not obstruct any portion of the gastrointestinal system.

Systems and methods define an index of risk for cardiac disease by detecting cellular derangements that may lead to cardiomyopathy, heart rhythm disorders or ischemic heart disease. The markers include fluctuations or abnormal rate-behavior of electrical, mechanical or other measurable biosignals. The invention operates in modes that can be applied to prevent atrial fibrillation or the risk for ventricular arrhythmias. Alternative embodiments are applied to tissue outside the heart such as skeletal muscle, smooth muscle, the central nervous system, the respiratory system, the urogenital system and the gastrointestinal system.

The invention provides a method of regulating water and mucin secretions and fluid transport in the gastrointestinal tract. The invention also provides a method for treating a gastrointestinal disease in which the mucosal barrier of the gastrointestinal system is impaired. The invention additionally provides a method for correcting disorders of fluid secretion or absorption in the gastrointestinal system. The method comprises administering to a patient a pharmaceutical composition comprising a purinergic P2Y receptor agonist, in an amount effective to regulate water and mucin secretions or to correct abnormal fluid transport in the gastrointestinal tract. The pharmaceutical composition used in this invention comprises a P2Y purinergic receptor agonist such as uridine 5'-diphosphate (UDP), uridine 5'-triphosphate (UTP), cytidine 5'-diphosphate (CDP), cytidine 5'-triphosphate (CTP), adenosine 5'-diphosphate (ADP), adenosine 5'-triphosphate (ATP), and their analogs; and dinucleotide polyphosphate compounds of general Formula (IV). Said compound is prepared in an oral form, an injectable form, or a suppository form, and administered to a patient.

A gastrointestinal system including a carrier including an actuator in operative communication with at least one traction member, the actuator moving the at least one traction member relative to the carrier, wherein the at least one traction member is movably supported across supports extending from the carrier, and wherein a portion of the at least one traction member between the supports is sufficiently compliant so as to deform in conformance with a shape of a gastrointestinal tract during traction therealong.

The present invention is directed to methods for stimulating the motility of the gastrointestinal system in a patient which comprises administering a growth hormone secretagogue, a prodrug thereof or a pharmaceutically acceptable salt of said secretagogue or said prodrug. More particularly, the present invention provides methods for stimulating the motility of the gastrointestinal system in a patient which comprises administering a compound of Formula I:

a prodrug thereof or a pharmaceutically acceptable salt of said secretagogue or said prodrug.

A system and method for evaluating gastrointestinal motility and, optionally, other physiological characteristics (e.g., pulse rate) that can be effectively employed to acquire one or more signals associated with acoustic energy (i.e. sound) emanating from an abdominal region of a body and determine at least one gastrointestinal parameter or event based on the acoustic energy signal(s) is described. The gastrointestinal parameter can include a gastrointestinal event, including gastrointestinal mixing, emptying, contraction and propulsion, and gastrointestinal transit time, or a gastrointestinal system disorder, including reflux disease, irritable bowel disease, ulcerative colitis, constipation, diarrhea, and a migrating motor complex disorder.

Disclosed are compounds that modulate the activity of the gated ion channels. Compounds that modulate these gated ion channels are useful in the treatment of diseases and disorders related to pain, inflammation, the neurological system, the gastrointestinal system and genitourinary system. Preferred compounds include compounds of the Formulae 1, 2, 3, 4, and 5.

In general, the invention is directed to systems and methods for monitoring the gastrointestinal system of a patient. In one embodiment, the invention includes techniques for monitoring the emptying of the patient's stomach. The techniques may employ glucose monitoring, pH monitoring with a consumable sensor, of monitoring the position of a consumable sensor as it exits the stomach. Consumable sensors may be employed to sense conditions, such as temperature or bile concentration, in other segments of the gastrointestinal system. The invention also includes systems for tracking the position of one or more consumable sensors as the sensors transit the gastrointestinal system, and monitoring the conditions sensed by the sensors.

Systems, devices and methods for enteral feeding that, in some arrangements, are powered by energy produced by a user of the system. Other arrangements utilize an external source of power. Generally, the systems include a storage assembly configured to hold a nutritional substance to be delivered to the gastrointestinal system of a user, such as through a feeding tube. The systems may include a pump unit, which can be manual, mechanical, hydraulic or electric. In some arrangements, the pump unit is separate from the storage assembly.

The invention discloses a processing method and a formula of longan ferment capable of soothing nerves and invigorating intestines and stomach. The longan ferment is naturally fermented by multiple fruits and vegetables, such as fresh fruits (in particular a pineapple), dried longan (longan pulp), plant beans, and the like, the essence of the fruits and the vegetables can be extracted, and products have abundant plant water soluble fibers, such as fruits and the like, and sufficient trace elements, such as vitamins, amino acid, minerals and the like, which are necessary for a human body; meanwhile, according to the invention, through design of a reasonable formula utilizing diversified composite ferment and probiotics as a main action, the longan ferment has the effects of lowering fire, moistening intestines, relaxing the bowels, improving sleep and the like, an a gastrointestinal system is taken as the principle thing (an intestinal tract and a bacterial phase are conserved), and functional food is supplemented, so that peristalsis of the intestinal tract can be promoted so as to release the stool.

The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and/or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in animals or humans in need thereof. Also provided is a liposome-based delivery of drugs, e.g., antibiotics, pain treatments and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system and other organs or body systems. In particular, liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin and toxins, such as botulinum toxin is provided for the treatment of bladder conditions, including pain, inflammation, incontinence and voiding dysftunction.

The present invention includes the following steps: 1. creating multichannel artificial simulated gastrointestinal system; 2. collecting and processing soil sample; 3. preparing artificial digestive juice; 4. adding the soil sample and artificial digestive juice into the multichannel artificial simulated gastrointestinal system; 5. under a certain reaction condition, after a certain time collecting a certain quantity of water sample from reaction container of system artificial gastrointestinal reactor; and 6. filtering and determining dissolved heavy metal pollutant content in the water sample. The invented method can be used for evaluating effectiveness of soil pollution to human body health risk.